March 14, 2013PLoS ONEOpen Access

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse

View Full Paper

Ask AI

Bookmark

Why the study?

Does non-pegylated liposomal-doxorubicin reduce cardiac toxicity compared to doxorubicin and epirubicin in preclinical models?

Structured PICO

Does non-pegylated liposomal-doxorubicin reduce cardiac toxicity compared to doxorubicin and epirubicin in preclinical models?

Population

HL-1 adult cardiomyocytes in culture and healthy CF-1 mice (n=10/group)

Intervention

Non-pegylated liposomal-doxorubicin (1 µM in vitro, 10 mg/kg in vivo)

Comparator

Doxorubicin and epirubicin (1 µM in vitro, 10 mg/kg in vivo)

Outcome

Reactive oxygen generation, DNA damage, and apoptotic cell death in vitro; left ventricular ejection fraction (LVEF), heart rate (HR), and cardiac output (CO) in vivo at 10 dayssafety

Non-pegylated liposomal doxorubicin exhibits reduced cardiotoxicity compared to standard doxorubicin and epirubicin in preclinical models.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports reduced cardiotoxicity hypothesis in models; leaves open clinical translation and requires human trials before practice change.

Cite This Study

Toldo et al. (2013) studied this question.

synapsesocial.com/papers/6a796a2702ab7a73dd02558e https://doi.org/10.1371/journal.pone.0058421

Topics

Echocardiography

View Full Paper

Ask AI

Bookmark

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse

Structured PICO

Discussion

Implication

Cite This Study

Topics

Comparative Cardiac Toxicity of Anthracyclines In Vitro and In Vivo in the Mouse

Structured PICO

Discussion

Implication

Cite This Study

Keep reading

Topics

Keep reading